Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INBRX-109 in Unresectable or Metastatic Conventional Chondrosarcoma
2021-002635-35Phase 2Active
- Sponsor
- Inhibrx, Inc.
- Start
- Dec 2021
- Modality
- Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in chondrosarcoma comparing INBRX-109 with Placebo (2 arms). Primary endpoint: Progression-free survival. Started Dec 2021; status: active.
02
Drugs
ozekibart
03
Conditions
chondrosarcoma
Beyond the preview
Go deeper on 2021-002635-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-002635-35.